Peer-reviewed veterinary case report
Survival after radiation for dogs with facial bone osteosarcoma
By Altwal, Johnny et al.·Published in Veterinary and comparative oncology·2024·College of Veterinary Medicine and Biomedical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy.
- Species:
- dog
Plain-English summary
A group of 35 dogs with craniomaxillofacial osteosarcoma (a type of bone cancer affecting the skull and face) were treated with a specialized radiation therapy called stereotactic body radiation therapy (SBRT) when surgery wasn't an option. The dogs had varying survival times, with an average of about 232 days after treatment. Those who received chemotherapy along with multiple radiation sessions tended to live longer than those who didn't. While some dogs experienced side effects, the combination of chemotherapy and SBRT showed promise for managing this challenging cancer.
People also search for: dog osteosarcoma treatment · stereotactic radiation therapy for dogs · dog cancer survival rates · chemotherapy for dog bone cancer · side effects of radiation therapy in dogs
Abstract
Canine craniomaxillofacial osteosarcoma (OSA) is most commonly treated surgically; however, in cases where surgery is not feasible or non-invasive treatment is desired, stereotactic body radiation therapy (SBRT) may be elected for local tumour control. In this study, we evaluated 35 dogs treated with SBRT. Nine dogs (26%) had calvarial, seven (20%) had mandibular and 19 (54%) had maxillary OSA. Median time to first event (TFE) was 171 days, and overall median survival time (MST) was 232 days. Site-specific MSTs were 144 days for mandible, 236 days for calvarium and 232 days for maxilla (p = .49). Pulmonary metastatic disease was observed in 12/35 (34%) patients and was detected pre-SBRT in six dogs (17%) and post-SBRT in the remaining six dogs (17%). Eighteen adverse events post-SBRT were documented. Per veterinary radiation therapy oncology group criteria, five were acute (14%) and three were late (9%) grade 3 events. Neurological signs in two dogs were suspected to be early-delayed effects. Cause of death was local progression for 22/35 (63%) patients, metastasis for 9/35 (26%) patients and unknown for four. On univariate analysis, administration of chemotherapy was associated with a longer TFE (p = .0163), whereas volume of gross tumour volume was associated with a shorter TFE (p = .023). Administration of chemotherapy and five fractions versus single fraction of SBRT was associated with increased survival time (p = .0021 and .049). Based on these findings, a treatment protocol incorporating chemotherapy and five fractions of SBRT could be considered for dogs with craniomaxillofacial OSA electing SBRT with careful consideration of normal tissues in the field.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38246695/